Streetbeat News

Products Services

BMR

NVDA

NVIDIA Corporation has announced the release of Video Codec SDK 12.1, which includes new APIs to support Beamr Imaging Ltd.'s Content Adaptive Bit Rate (CABR) library. This collaboration aims to deliver high-quality encoding at the lowest possible bit rate.

Portfolio Pulse from Charles Gross

May 25, 2023 | 12:08 pm

TLRY

Tilray Brands' medical cannabis division, Tilray Medical, and its Italian subsidiary FL Group have received authorization from Italy's Ministry of Health to distribute three new medical cannabis compounds. Tilray also announced a partnership with Pharmaidea to market and educate over 12,000 pharmacies across Italy on medical cannabis patient care.

Portfolio Pulse from Vuk Zdinjak

May 25, 2023 | 12:06 pm

IMMP

Immutep has dosed its first patient in the AIPAC-003 Phase II/III trial for metastatic breast cancer. The trial aims to evaluate the safety and efficacy of the company's lead product candidate, eftilagimod alpha.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:00 pm

DYN

Dyne Therapeutics has received Orphan Drug Designation from the European Medicines Agency (EMA) for its product DYNE-101, which aims to treat a rare genetic disorder.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 11:35 am

BTAI

BioXcel Therapeutics announced topline results from Part 1 of the pivotal SERENITY III trial of BXCL501 for at-home use in acute treatment of agitation in bipolar disorders or schizophrenia, achieving a greater than 50% PEC response rate.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 11:09 am

VNDA

Vanda Pharmaceuticals announced positive results from its Phase III study of tradipitant in motion sickness, showing its effectiveness in preventing vomiting. The company plans to continue the clinical program and pursue FDA approval after completing additional efficacy and safety studies.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 11:08 am

APLT

The European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation to Applied Therapeutics' AT-007 (Govorestat) for the treatment of Sorbitol Dehydrogenase (SORD) deficiency.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 11:06 am

APLS

Apellis Pharmaceuticals and Sobi announced that their Phase 2 MERIDIAN study in ALS did not meet its primary endpoint. Due to the lack of efficacy, the companies plan to discontinue the development of systemic pegcetacoplan for ALS.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 11:06 am

TM

Lexus is set to unveil the all-new GX SUV on June 8th in Austin, Texas. The GX is a genuine off-road SUV, catering to the needs of adventurous customers.

Portfolio Pulse from Charles Gross

May 25, 2023 | 11:05 am

BMY

JNJ

Bristol Myers Squibb and Janssen announce that their drug Milvexian has been granted US FDA Fast Track Designation for all three indications under evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome, and Atrial Fibrillation.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 10:59 am